advanced gastric cancer
Conditions
Interventions
L-OHP,130mg/m2 DIV on day1 S-1,80 to 120mg/m2 PO on day1 to 14 1 cycle,3 weeks Continue for 4 cycles After 4 cycles,S-1 alone is continued 4 cycles
Sponsors
Department of Surgery, Gastroenterological Center, Medical Center, Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically proven adenocarcinoma 2. Unresectable advanced gastric cancer 3. No massive ascites 4. No metastasis to the central nervous system 5. Patients with and without measurable lesion 6. Possible to oral intake 7. PS: 0 or 1 8. HER2 negative 9. No previous chemothearpy a. more than 24 weeks after S-1 administration completed b. no more than 1040mg/m2 of oxalipalatin 10. no lethal disfunction of the major organs 11. Who gave informed consent
Exclusion criteria
Exclusion criteria: 1. Drug allergy 2. Peripheral neurodisturvance 3. GI tract bleeding 4. Continuation of phenitoin, warfain 5. Uncontrollable infection 6. Interstitial pneumonia 7. Other cancers 8. DPD deficiency 9. Family planning 10. Inappropriate patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate, overall survival, toxicity | — |
Countries
Japan
Contacts
Public ContactChikara Kunisaki
Medical Center, Yokohama City University Department of Surgery, Gastroenterological Center
Outcome results
None listed